# Lona L Christrup

List of Publications by Year
in descending order



| 87 | 3,061 | 249298 | 190340 |
|---|---|---|---|
| papers | citations | 26 h-index | 53 g-index |

| 90 | 90 | 90 | 3370 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Oral absorption of oxycodone in patients with short bowel syndrome. Scandinavian Journal of Gastroenterology, 2021, 56, 1023-1029. | 0.6 | 1 |
| 2 | Effect of Rouxâ€enâ€Y gastric bypass on the pharmacokineticâ€pharmacodynamic relationships of liquid and controlledâ€release formulations of oxycodone. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 232-245. | 1.2 | 3 |
| 3 | Population pharmacokineticâ€pharmacodynamic modelling of liquid and controlledâ€release formulations of oxycodone in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 263-276. | 1.2 | 13 |
| 4 | Chronic abdominal pain and persistent opioid use after bariatric surgery. Scandinavian Journal of Pain, 2020, 20, 239-251. | 0.5 | 15 |
| 5 | Differences in Kidney Function Estimates Based on Creatinine and/or Cystatin C in Non-Traumatic Amputation Patients and Their Impact on Drug Prescribing. Journal of Clinical Medicine, 2019, 8, 89. | 1.0 | 6 |
| 6 | Healthcare professionalsâ€™ agreement on clinical relevance of drug-related problems among elderly patients. International Journal of Clinical Pharmacy, 2018, 40, 119-125. | 1.0 | 4 |
| 7 | Association Between Genetic Polymorphisms and Pain Sensitivity in Patients with Hip Osteoarthritis. Pain Practice, 2018, 18, 587-596. | 0.9 | 25 |
| 8 | Recreational drug use at a major music festival: trend analysis of anonymised pooled urine. Clinical Toxicology, 2018, 56, 245-255. | 0.8 | 13 |
| 9 | Creatinine-Based Renal Function Estimates and Dosage of Postoperative Pain Management for Elderly Acute Hip Fracture Patients. Pharmaceuticals, 2018, 11, 88. | 1.7 | 6 |
| 10 | Offset Analgesia and The Impact of Treatment with Oxycodone and Venlafaxine: A Placeboâ€Controlled, Randomized Trial in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 727-731. | 1.2 | 12 |
| 11 | Genetic Influences of <scp>OPRM</scp>1,<scp>OPRD</scp>1 and <scp>COMT</scp> on Morphine Analgesia in a Multiâ€Modal, Multiâ€Tissue Human Experimental Pain Model. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 6-12. | 1.2 | 18 |
| 12 | Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 325-333. | 0.8 | 4 |
| 13 | Objective methods for the assessment of the spinal and supraspinal effects of opioids. Scandinavian Journal of Pain, 2017, 14, 15-24. | 0.5 | 13 |
| 14 | Cortical and spinal assessment - a comparative study using encephalography and the nociceptive withdrawal reflex. Journal of Pharmacological and Toxicological Methods, 2017, 84, 37-43. | 0.3 | 3 |
| 15 | Association between Gene Polymorphisms and Pain Sensitivity Assessed in a Multiâ€Modal Multiâ€Tissue Human Experimental Model â€“ An Explorative Study. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 360-366. | 1.2 | 8 |
| 16 | Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunctionâ€“Recommendations of the Nordic Working Group. Scandinavian Journal of Pain, 2016, 11, 111-122. | 0.5 | 73 |
| 17 | A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain. Pharmaceutical Research, 2016, 33, 1093-1103. | 1.7 | 13 |
| 18 | A Model-Based Approach for Joint Analysis of Pain Intensity and Opioid Consumption in Postoperative Pain. AAPS Journal, 2016, 18, 1013-1022. | 2.2 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Short-term oxycodone treatment does not affect electrogenic ion transport in isolated mucosa from the human rectosigmoid colon. Scandinavian Journal of Gastroenterology, 2016, 51, 538-547. | 0.6 | 2 |
| 20 | Repeated Time-to-event Analysis of Consecutive Analgesic Events in Postoperative Pain. Anesthesiology, 2015, 123, 1411-1419. | 1.3 | 28 |
| 21 | Exploratory survey study of long-term users of nicotine replacement therapy in Danish consumers. Harm Reduction Journal, 2015, 12, 2. | 1.3 | 5 |
| 22 | Symptoms and side effects in chronic nonâ€cancer pain patients: clinical implications and development of new assessment tools. Acta Anaesthesiologica Scandinavica, 2015, 59, 1060-1067. | 0.7 | 0 |
| 23 | Association Between Human Painâ€Related Genotypes and Variability in Opioid Analgesia: An Updated Review. Pain Practice, 2015, 15, 580-594. | 0.9 | 56 |
| 24 | Disruption of Cortical Connectivity during Remifentanil Administration Is Associated with Cognitive Impairment but Not with Analgesia. Anesthesiology, 2015, 122, 140-149. | 1.3 | 15 |
| 25 | Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration â€“ A dose escalation study. European Journal of Pharmaceutical Sciences, 2015, 68, 78-86. | 1.9 | 8 |
| 26 | Objective markers of the analgesic response to morphine in experimental pain research. Journal of Pharmacological and Toxicological Methods, 2015, 73, 7-14. | 0.3 | 7 |
| 27 | A review of morphine and morphine-6-glucuronideâ€™s pharmacokineticâ€“pharmacodynamic relationships in experimental and clinical pain. European Journal of Pharmaceutical Sciences, 2015, 74, 45-62. | 1.9 | 92 |
| 28 | Does mutual compensation of the cognitive effects induced by pain and opioids exist? An experimental study. Psychopharmacology, 2015, 232, 1373-1381. | 1.5 | 10 |
| 29 | Altered Frequency Distribution in the Electroencephalogram is Correlated to the Analgesic Effect of Remifentanil. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 414-422. | 1.2 | 17 |
| 30 | A cortical source localization analysis of resting EEG data after remifentanil infusion. Clinical Neurophysiology, 2015, 126, 898-905. | 0.7 | 10 |
| 31 | Modelling concentrationâ€“analgesia relationships for morphine to evaluate experimental pain models. European Journal of Pharmaceutical Sciences, 2015, 66, 50-58. | 1.9 | 10 |
| 32 | Pharmacodynamic Modelling of Placebo and Buprenorphine Effects on Eventâ€Related Potentials in Experimental Pain. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 343-351. | 1.2 | 4 |
| 33 | Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics, 2014, 24, 185-194. | 0.7 | 42 |
| 34 | Quality of life and symptoms in patients with malignant diseases admitted to a comprehensive cancer centre. Supportive Care in Cancer, 2014, 22, 1843-1849. | 1.0 | 11 |
| 35 | Pharmacokineticâ€“Pharmacodynamic Modelling of the Analgesic and Antihyperalgesic Effects of Morphine after Intravenous Infusion in Human Volunteers. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 257-267. | 1.2 | 7 |
| 36 | Altered cortical causality after remifentanil administration in healthy volunteers: A novel approach for pharmaco-EEG. , 2014, 2014, 4290-3. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Barriers to Cancer Pain Management in Danish and Lithuanian Patients Treated in Pain and Palliative Care Units. Pain Management Nursing, 2014, 15, 51-58. | 0.4 | 13 |
| 38 | Differences between opioids: pharmacological, experimental, clinical and economical perspectives. British Journal of Clinical Pharmacology, 2013, 75, 60-78. | 1.1 | 150 |
| 39 | Morphine- and buprenorphine-induced analgesia and antihyperalgesia in a human inflammatory pain model: a double-blind, randomized, placebo-controlled, five-arm crossover study. Journal of Pain Research, 2013, 6, 23. | 0.8 | 26 |
| 40 | Switching from high doses of pure Âμ-opioid agonists to transdermal buprenorphine in patients with cancer: A feasibility study. Journal of Opioid Management, 2013, 9, 255-262. | 0.2 | 8 |
| 41 | Effect of intraoral and subcutaneous morphine on dyspnea at rest in terminal patients with primary lung cancer or lung metastases. Journal of Opioid Management, 2013, 9, 269-274. | 0.2 | 24 |
| 42 | A physiologically-based recirculatory meta-model for nasal fentanyl in man. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 561-576. | 0.8 | 11 |
| 43 | Prediction of pain sensitivity in healthy volunteers. Journal of Pain Research, 2012, 5, 313. | 0.8 | 37 |
| 44 | Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 274-284. | 1.2 | 36 |
| 45 | The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial. Journal of Hypertension, 2010, 28, 194-200. | 0.3 | 55 |
| 46 | Psychological and behavioural predictors of pain management outcomes in patients with cancer. Scandinavian Journal of Caring Sciences, 2010, 24, 781-790. | 1.0 | 19 |
| 47 | A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. Clinical Pharmacokinetics, 2010, 49, 817-827. | 1.6 | 24 |
| 48 | Rationales behind the choice of administration form with fentanyl: Delphi survey among Danish general practitioners. Journal of Opioid Management, 2010, 6, 259-268. | 0.2 | 2 |
| 49 | Translational pain research: Evaluating analgesic effect in experimental visceral pain models. World Journal of Gastroenterology, 2009, 15, 177. | 1.4 | 14 |
| 50 | Survey of patient and physician assessment of a compliance reminder device in the treatment of hypertension. Blood Pressure, 2009, 18, 280-285. | 0.7 | 0 |
| 51 | Role of active metabolites in the use of opioids. European Journal of Clinical Pharmacology, 2009, 65, 121-139. | 0.8 | 95 |
| 52 | The Danish version of the Medication Adherence Report Scale: Preliminary Validation in Cancer Pain Patients. Pain Practice, 2009, 9, 1-7. | 0.9 | 17 |
| 53 | The Danish Barriers Questionnaireâ€¦: Preliminary Validation in Cancer Pain Patients. Pain Practice, 2009, 9, 266-274. | 0.9 | 11 |
| 54 | Danish Pain Specialists' Rationales behind the Choice of Fentanyl Transdermal Patches and Oral Transmucosal Systemsâ€"A Delphi Study. Pain Medicine, 2009, 10, 1442-1451. | 0.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Patientâ€related barriers to cancer pain management: a systematic exploratory review. Scandinavian Journal of Caring Sciences, 2009, 23, 190-208. | 1.0 | 99 |
| 56 | Survey of patient and physician assessment of a compliance reminder device in the treatment of hypertension. Blood Pressure, 2009, 18, 280-285. | 0.7 | 7 |
| 57 | Novel formulations and routes of administration for opioids in the treatment of breakthrough pain. Therapy: Open Access in Clinical Medicine, 2009, 6, 695-706. | 0.2 | 10 |
| 58 | Pharmacokineticâ€“Pharmacodynamic Relationships of Cognitive and Psychomotor Effects of Intravenous Buprenorphine Infusion in Human Volunteers. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 94-101. | 1.2 | 26 |
| 59 | Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clinical Therapeutics, 2008, 30, 469-481. | 1.1 | 106 |
| 60 | Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery. Annals of Pharmacotherapy, 2008, 42, 1380-1387. | 0.9 | 80 |
| 61 | Pharmacokineticâ€Pharmacodynamic Modeling of Morphine and Oxycodone Concentrations and Analgesic Effect in a Multimodal Experimental Pain Model. Journal of Clinical Pharmacology, 2008, 48, 619-631. | 1.0 | 54 |
| 62 | Patient acceptance of a tablet reminder device. Journal of Medical Marketing, 2007, 7, 152-161. | 0.2 | 2 |
| 63 | Differential effect of opioids in patients with chronic pancreatitis: An experimental pain study. Scandinavian Journal of Gastroenterology, 2007, 42, 383-390. | 0.6 | 84 |
| 64 | Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers. European Journal of Clinical Pharmacology, 2007, 63, 761-767. | 0.8 | 9 |
| 65 | Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. European Journal of Clinical Pharmacology, 2007, 63, 1153-1159. | 0.8 | 19 |
| 66 | Physician-related barriers to cancer pain management with opioid analgesics: A systematic review. Journal of Opioid Management, 2007, 3, 207-214. | 0.2 | 78 |
| 67 | Pharmacokinetics of M6G following intravenous and oral administration in healthy volunteers. Acute Pain, 2006, 8, 63-71. | 0.1 | 5 |
| 68 | A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain, 2006, 123, 28-36. | 2.0 | 138 |
| 69 | Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. European Journal of Pain, 2005, 9, 453-453. | 1.4 | 108 |
| 70 | Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. European Journal of Pharmaceutical Sciences, 2005, 24, 297-303. | 1.9 | 98 |
| 71 | Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. European Journal of Pain, 2004, 8, 263-271. | 1.4 | 16 |
| 72 | Medicated Chewing Gum. American Journal of Drug Delivery, 2004, 2, 75-88. | 0.6 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Relationships Among Morphine Metabolism, Pain and Side Effects During Long-Term Treatment. Journal of Pain and Symptom Management, 2003, 25, 74-91. | 0.6 | 125 |
| 74 | Changing M3G/M6G Ratios and Pharmacodynamics in a Cancer Patient During Long-Term Morphine Treatment. Journal of Pain and Symptom Management, 2002, 23, 161-164. | 0.6 | 19 |
| 75 | Steady-State Kinetics and Dynamics of Morphine in Cancer Patients. Journal of Pain and Symptom Management, 1999, 18, 164-173. | 0.6 | 18 |
| 76 | Opioid analgesics as noncompetitive N-methyl-d-aspartate (NMDA) antagonists. Biochemical Pharmacology, 1998, 56, 553-559. | 2.0 | 149 |
| 77 | Recommended use of morphine in neonates, infants and children based on a literature review: Part 1â€"Pharmacokinetics. Paediatric Anaesthesia, 1997, 7, 5-11. | 0.6 | 183 |
| 78 | Recommended use of morphine in neonates, infants and children based on a literature review: Part 2â€"Clinical use. Paediatric Anaesthesia, 1997, 7, 93-101. | 0.6 | 135 |
| 79 | The mu<sub>1</sub> and mu<sub>2</sub> opioid receptor binding of ketobemidone, norketobemidone and 3â€dimethylaminoâ€1,1â€diphenylbutene. Basic and Clinical Pharmacology and Toxicology, 1996, 79, 103-104. | 0.0 | 4 |
| 80 | Stereoselective Pharmacokinetics of Methadone in Chronic Pain Patients. Therapeutic Drug Monitoring, 1996, 18, 221-227. | 1.0 | 120 |
| 81 | The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sciences, 1994, 56, 45-50. | 2.0 | 156 |
| 82 | Enhanced transdermal delivery of ketobemidone with prodrugs. International Journal of Pharmaceutics, 1992, 84, 253-260. | 2.6 | 6 |
| 83 | Saliva-catalyzed hydrolysis of a ketobemidone ester prodrug: Factors influencing human salivary esterase activity. International Journal of Pharmaceutics, 1992, 88, 221-227. | 2.6 | 9 |
| 84 | Ketobemidone prodrugs for buccal delivery: Prediction of the extent of saliva-catalyzed hydrolysis of various ester prodrugs under simulated in vivo conditions. International Journal of Pharmaceutics, 1992, 88, 229-235. | 2.6 | 6 |
| 85 | Enhanced delivery of ketobemidone through porcine buccal mucosa in vitro via more lipophilic ester prodrugs. International Journal of Pharmaceutics, 1992, 88, 237-242. | 2.6 | 22 |
| 86 | Buccal absorption of ketobemidone and various ester prodrugs in the rat. International Journal of Pharmaceutics, 1992, 88, 243-250. | 2.6 | 6 |
| 87 | Utilization of prodrugs to enhance the transdermal absorption of morphine. International Journal of Pharmaceutics, 1991, 71, 105-116. | 2.6 | 29 |